$IVVD News

BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target

The FDA Sent Invivyd An Advance Termination Notice For Pemgarda (Pemivibart) Emergency Use Authorization Following US Department Of Health And Human Services’ Announcement Of Advanced Notice Of Termination Of Covid-19 EUA Declaration On June 30, With Effective Date Of June 29, 2027

Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026

HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $10 Price Target

BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target

Invivyd Dosed The First Participants In LIBERTY Phase 3 Trial Of VYD2311 Alone, And VYD2311 Co-administered With A Covid-19 Vaccine In Healthy Adults; Topline Data Is Expected In Q3 2026, To Accompany Anticipated Data From Pivotal DECLARATION Study

Invivyd Completes Enrollment In DECLARATION Phase 3 Trial of VYD2311 To Prevent Symptomatic Covid-19; Top-line Data Expected In Approximately Late Q3 2026

BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target

BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target

Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now

Invivyd, Inc. 2026 Q1 - Results - Earnings Call Presentation

Invivyd Inc (IVVD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments

Invivyd Q1 Earnings Call Highlights

Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript

Invivyd (NASDAQ:IVVD) Q1 Miss Sends Shares Lower as PEMGARDA Revenue Falls Short and R&D Costs Surge

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Invivyd Reports Q1 2026 Results: Full Earnings Call Transcript

Invivyd Q1 EPS $(0.13) Misses $(0.07) Estimate, Sales $13.744M Miss $18.050M Estimate

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd EVADE Trial Data Reveals Monoclonal Antibody VYD2311 Demonstrates Minimal Tolerability Issues Versus COVID mRNA Vaccination